146 related articles for article (PubMed ID: 15994934)
21. Association of c-myc overexpression and hyperproliferation with arsenite-induced malignant transformation.
Chen H; Liu J; Zhao CQ; Diwan BA; Merrick BA; Waalkes MP
Toxicol Appl Pharmacol; 2001 Sep; 175(3):260-8. PubMed ID: 11559025
[TBL] [Abstract][Full Text] [Related]
22. Cooperation of Gata3, c-Myc and Notch in malignant transformation of double positive thymocytes.
van Hamburg JP; de Bruijn MJ; Dingjan GM; Beverloo HB; Diepstraten H; Ling KW; Hendriks RW
Mol Immunol; 2008 Jun; 45(11):3085-95. PubMed ID: 18471881
[TBL] [Abstract][Full Text] [Related]
23. MYC oncogene elicits tumorigenesis associated with embryonic, ribosomal biogenesis, and tissue-lineage dedifferentiation gene expression changes.
Sullivan DK; Deutzmann A; Yarbrough J; Krishnan MS; Gouw AM; Bellovin DI; Adam SJ; Liefwalker DF; Dhanasekaran R; Felsher DW
Oncogene; 2022 Nov; 41(45):4960-4970. PubMed ID: 36207533
[TBL] [Abstract][Full Text] [Related]
24. Role of MYC-regulated long noncoding RNAs in cell cycle regulation and tumorigenesis.
Kim T; Jeon YJ; Cui R; Lee JH; Peng Y; Kim SH; Tili E; Alder H; Croce CM
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25663692
[TBL] [Abstract][Full Text] [Related]
25. Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
Schlott T; Eiffert H; Bohne W; Landgrebe J; Brunner E; Spielbauer B; Knight B
Gynecol Oncol; 2005 Sep; 98(3):409-19. PubMed ID: 16005053
[TBL] [Abstract][Full Text] [Related]
26. Evolution of neoplastic development in the liver of transgenic mice co-expressing c-myc and transforming growth factor-alpha.
Santoni-Rugiu E; Nagy P; Jensen MR; Factor VM; Thorgeirsson SS
Am J Pathol; 1996 Aug; 149(2):407-28. PubMed ID: 8701981
[TBL] [Abstract][Full Text] [Related]
27. Hemopoietic neoplasms in lethally irradiated mice repopulated with bone marrow cells carrying the human c-myc oncogene: a repopulation assay.
Hirabayashi Y; Inoue T; Suda Y; Aizawa S; Ikawa Y; Kanisawa M
Exp Hematol; 1992 Feb; 20(2):167-72. PubMed ID: 1544384
[TBL] [Abstract][Full Text] [Related]
28. [The expression of C-myc oncogene in leukemia and its relationship to clinical symptoms].
Yang PM; Fu L
Zhonghua Nei Ke Za Zhi; 1992 Mar; 31(3):143-5, 187. PubMed ID: 1395924
[TBL] [Abstract][Full Text] [Related]
29. [The mouse ovarian surface epithelium cells (MOSE) transformation induced by c-myc/K-ras in].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Zhong Liu Za Zhi; 2006 Dec; 28(12):881-5. PubMed ID: 17533735
[TBL] [Abstract][Full Text] [Related]
30. E mu N- and E mu L-myc cooperate with E mu pim-1 to generate lymphoid tumors at high frequency in double-transgenic mice.
Möröy T; Verbeek S; Ma A; Achacoso P; Berns A; Alt F
Oncogene; 1991 Nov; 6(11):1941-8. PubMed ID: 1658705
[TBL] [Abstract][Full Text] [Related]
31. Tumor induction by the c-Myc target genes rcl and lactate dehydrogenase A.
Lewis BC; Prescott JE; Campbell SE; Shim H; Orlowski RZ; Dang CV
Cancer Res; 2000 Nov; 60(21):6178-83. PubMed ID: 11085542
[TBL] [Abstract][Full Text] [Related]
32. Alterations in specific gene expression and focal neoplastic growth during spontaneous hepatocarcinogenesis in albumin-SV40 T antigen transgenic rats.
Dragan YP; Sargent LM; Babcock K; Kinunen N; Pitot HC
Mol Carcinog; 2004 Jul; 40(3):150-9. PubMed ID: 15224347
[TBL] [Abstract][Full Text] [Related]
33. Sirt1 deacetylates c-Myc and promotes c-Myc/Max association.
Mao B; Zhao G; Lv X; Chen HZ; Xue Z; Yang B; Liu DP; Liang CC
Int J Biochem Cell Biol; 2011 Nov; 43(11):1573-81. PubMed ID: 21807113
[TBL] [Abstract][Full Text] [Related]
34. Role for E2F1 in p210 BCR-ABL downstream regulation of c-myc transcription initiation. Studies in murine myeloid cells.
Stewart MJ; Litz-Jackson S; Burgess GS; Williamson EA; Leibowitz DS; Boswell HS
Leukemia; 1995 Sep; 9(9):1499-507. PubMed ID: 7658719
[TBL] [Abstract][Full Text] [Related]
35. Role of SPA-1 in phenotypes of chronic myelogenous leukemia induced by BCR-ABL-expressing hematopoietic progenitors in a mouse model.
Kometani K; Aoki M; Kawamata S; Shinozuka Y; Era T; Taniwaki M; Hattori M; Minato N
Cancer Res; 2006 Oct; 66(20):9967-76. PubMed ID: 17047059
[TBL] [Abstract][Full Text] [Related]
36. Destruction of Myc by ubiquitin-mediated proteolysis: cancer-associated and transforming mutations stabilize Myc.
Salghetti SE; Kim SY; Tansey WP
EMBO J; 1999 Feb; 18(3):717-26. PubMed ID: 9927431
[TBL] [Abstract][Full Text] [Related]
37. MYC, metabolism, cell growth, and tumorigenesis.
Dang CV
Cold Spring Harb Perspect Med; 2013 Aug; 3(8):. PubMed ID: 23906881
[TBL] [Abstract][Full Text] [Related]
38. Transgenic mouse model for synergistic effects of nuclear oncogenes and growth factors in tumorigenesis: interaction of c-myc and transforming growth factor alpha in hepatic oncogenesis.
Murakami H; Sanderson ND; Nagy P; Marino PA; Merlino G; Thorgeirsson SS
Cancer Res; 1993 Apr; 53(8):1719-23. PubMed ID: 8467484
[TBL] [Abstract][Full Text] [Related]
39. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
[TBL] [Abstract][Full Text] [Related]
40. Disruption of the pRb/E2F pathway and inhibition of apoptosis are major oncogenic events in liver constitutively expressing c-myc and transforming growth factor alpha.
Santoni-Rugiu E; Jensen MR; Thorgeirsson SS
Cancer Res; 1998 Jan; 58(1):123-34. PubMed ID: 9426068
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
